PT  - JOURNAL ARTICLE
AU  - Wang, Yanru
AU  - Wang, Aoxuan
AU  - Xie, Ning
AU  - Xu, Xiaowen
AU  - Wang, Xiang
AU  - Zhao, Mengshen
AU  - Wang, Xuan
AU  - Zhou, Jiacheng
AU  - Zhao, Yang
AU  - Hu, Zhibin
AU  - Shen, Hongbing
AU  - Hung, Rayjean J.
AU  - Amos, Christopher I.
AU  - Li, Yi
AU  - Christiani, David C.
AU  - Chen, Feng
AU  - Wei, Yongyue
AU  - Zhang, Ruyang
TI  - An integrative analysis of consortium-based multi-omics QTL and genome-wide association study data uncovers new biomarkers for lung cancer
AID  - 10.1101/2024.12.13.24318992
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.12.13.24318992
4099  - http://medrxiv.org/content/early/2024/12/16/2024.12.13.24318992.short
4100  - http://medrxiv.org/content/early/2024/12/16/2024.12.13.24318992.full
AB  - The role of molecular traits (e.g., gene expression and protein abundance) in the occurrence, development, and prognosis of lung cancer has been extensively studied. However, biomarkers in other molecular layers and connections among various molecular traits that influence lung cancer risk remain largely underexplored. We conducted the first comprehensive assessment of the associations between molecular biomarkers (i.e., DNA methylation, gene expression, protein and metabolite) and lung cancer risk through epigenome-wide association study (EWAS), transcriptome-wide association study (TWAS), proteome-wide association study (PWAS) and metabolome-wide association study (MWAS), and then we synthesized all omics layers to reveal potential regulatory mechanisms across layers. Our analysis identified 61 CpG sites, 62 genes, 6 proteins, and 5 metabolites, yielding 123 novel biomarkers. These biomarkers highlighted 90 relevant genes for lung cancer, 83 among them were first established in our study. Multi-omics integrative analysis revealed 12 of these genes overlapped across omics layers, suggesting cross-omics interactions. Moreover, we identified 106 potential cross-layer regulatory pathways, indicating that cell proliferation, differentiation, immunity, and protein-catalyzed metabolite reaction interact to influence lung cancer risk. Further subgroup analyses revealed that biomarker distributions differ across patient subgroups. To share all signals in different omics layers with community, we released a free online platform, LungCancer-xWAS, which can be accessed at http://bigdata.njmu.edu.cn/LungCancer-xWAS/. Our findings underscore the importance of xWAS which integrating various types of molecular quantitative trait loci (xQTL) data with genome-wide association study (GWAS) data to deepen understanding of lung cancer pathophysiology, which may provide valuable insights into potential therapeutic targets for the disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: This study was funded by the National Natural Science Foundation of China (81530088 to F.C., 82273737 to R.Z., 82373690 to Y.Z., and 81973142 to Y.W.), US National Institutes of Health (CA209414, HL060710 and ES000002 to D.C.C.) and Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). R.Z. was partially supported by the Qing Lan Project of the Higher Education Institutions of Jiangsu Province and the Outstanding Young Level Academic Leadership Training Program of Nanjing Medical University. *Correspondence: Ruyang Zhang (zhangruyang{at}njmu.edu.cn); Feng Chen (fengchen{at}njmu.edu.cn); Yang Zhao (zhaoyang{at}njmu.edu.cn); Yongyue Wei (ywei{at}pku.edu.cn); David C Christiani (dchris{at}hsph.harvard.edu).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Nanjing Medical University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes